HEALTH

Three Lawmakers Bought Boston Scientific Stock Within Weeks of Each Other

Sen. Moran and Reps. Pelosi and Dunn disclosed purchases of the med-tech giant between March and May, a cluster that mirrors the broader market rally in device makers.

By Franc Alagbe·June 28, 2026·◷ 3 min$BSX $GOOGL $BRK.B $UBER $INTC $GD

U.S. Capitol at dawn with a symbolic stock ticker showing BSX and medical device symbols

A Quiet Consensus on a Device Giant

Three members of Congress — spanning both parties and both chambers — disclosed purchases of Boston Scientific (BSX) shares during a roughly two-month window this spring, according to STOCK Act filings made public in late June. The overlap is notable because it occurred without any single hearing, markup, or piece of legislation that would obviously tie the company to imminent congressional action.

Sen. Jerry Moran (R‑Kan.) filed a disclosure on June 25 showing a purchase of $1,001–$15,000 in BSX on May 27. Rep. Nancy Pelosi (D‑Calif.) reported a spouse purchase of $500,001–$1,000,000 on May 29, filed June 23. Rep. Neal Dunn (R‑Fla.) disclosed a $15,001–$50,000 buy on March 27, filed June 24. All three transactions were coded as purchases; none were sales.

Why the Cluster Matters

Algorithmic screening flags this as a "herd" signal: three lawmakers buying the same ticker within 63 days, with a combined mid‑point volume of roughly $64,500. The herd score of 32 places it in the middle tier — not a red‑alert conviction trade, but enough to warrant a second look. None of the three sit on committees with direct jurisdiction over medical‑device regulation or Medicare reimbursement, which reduces the immediate conflict‑of‑interest flag but does not eliminate the perception risk.

Boston Scientific shares rose about 18 % between late March and late May, outperforming the S&P 500’s 6 % gain over the same span. The company reported first‑quarter earnings on April 23 that beat consensus, raised full‑year guidance, and highlighted strength in its electrophysiology and structural‑heart franchises — catalysts fully available to the public.

The Disclosure Lag Reminder

By law, members have up to 45 days after a trade to file their periodic transaction reports. The filings cited here became public between June 23 and June 25, meaning the actual trades occurred 25 to 93 days earlier. Investors watching congressional portfolios in real time are always reacting to stale data.

Other Notable Filings This Week

While the BSX cluster draws the headline, the same batch of disclosures showed:

Sen. Moran also sold Alphabet (GOOGL) and bought Berkshire Hathaway (BRK.B) on May 27.
Rep. Pelosi’s spouse bought Uber (UBER) and a large block of Intel (INTC) on May 29.
Rep. Dwight Evans (D‑Pa.) sold General Dynamics (GD) and Intel on June 10.
Rep. Dunn sold AT&T (T) and Regions Financial (RF) bonds on May 11.

What to Watch

No BSX‑specific legislation is on the immediate calendar. The House Energy & Commerce Health Subcommittee — the panel with the clearest oversight of device regulation — has no markups scheduled this week. The next meaningful policy catalyst for the sector would be movement on the VERA Act (site‑neutral payments) or PDUFA reauthorization, both still in early committee stages.

This analysis is based solely on public STOCK Act disclosures. It is not investment advice and does not allege wrongdoing; congressional trading is legal and disclosed on a delayed basis.